CorMedix Business Update
CorMedix provided a business update reporting a cash position of approximately $355 million as of September 30, 2026, and reaffirmed its full-year 2026 revenue guidance. The company also addressed the CMS 2027 ESRD PPS final rule regarding DefenCath reimbursement, projecting that the average 2027 Add-on rate will be more than double the current rate.